Bioventus Stock Performance
| BVS Stock | USD 7.82 0.06 0.77% |
On a scale of 0 to 100, Bioventus holds a performance score of 8. The firm shows a Beta (market volatility) of 1.04, which signifies a somewhat significant risk relative to the market. Bioventus returns are very sensitive to returns on the market. As the market goes up or down, Bioventus is expected to follow. Please check Bioventus' semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Bioventus' price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Bioventus are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Bioventus unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (2.02) | Five Day Return (4.32) | Year To Date Return 7.63 | Ten Year Return (59.60) | All Time Return (59.60) |
1 | Bioventus Shares Gap Up Whats Next | 11/04/2025 |
2 | Bioventus Shares Up 9.9 percent Whats Next | 11/21/2025 |
3 | Insider Selling GUY NOHRA Unloads 75K Of Bioventus Stock | 12/09/2025 |
4 | Will Bioventus Inc. stock deliver consistent dividends - Portfolio Risk Summary AI Enhanced Market Trend Forecasts - DonanmHaber | 12/19/2025 |
5 | Bravura Solutions and Emerging ASX Penny Stocks Gaining Market Attention | 12/23/2025 |
6 | Acquisition by Mark Singleton of 18625 shares of Bioventus subject to Rule 16b-3 | 12/29/2025 |
7 | Acquisition by Robert Claypoole of 93750 shares of Bioventus subject to Rule 16b-3 | 12/31/2025 |
8 | Disposition of 93750 shares by Robert Claypoole of Bioventus subject to Rule 16b-3 | 01/06/2026 |
9 | Disposition of 41717 shares by Robert Claypoole of Bioventus at 8.03 subject to Rule 16b-3 | 01/09/2026 |
10 | Bioventus Stock Price Down 0.6 percent - Should You Sell - MarketBeat | 01/13/2026 |
11 | Bioventus Details Turnaround Plan, Four Growth Drivers at J.P. Morgan Conference | 01/16/2026 |
12 | Acquisition by Stalnecker Susan M of 26493 shares of Bioventus subject to Rule 16b-3 | 01/27/2026 |
| Begin Period Cash Flow | 37 M | |
| Total Cashflows From Investing Activities | 23 M |
Bioventus | Build AI portfolio with Bioventus Stock |
Bioventus Relative Risk vs. Return Landscape
If you would invest 655.00 in Bioventus on October 31, 2025 and sell it today you would earn a total of 127.00 from holding Bioventus or generate 19.39% return on investment over 90 days. Bioventus is generating 0.343% of daily returns assuming volatility of 3.3188% on return distribution over 90 days investment horizon. In other words, 29% of stocks are less volatile than Bioventus, and above 94% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Bioventus Target Price Odds to finish over Current Price
The tendency of Bioventus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 7.82 | 90 days | 7.82 | about 17.14 |
Based on a normal probability distribution, the odds of Bioventus to move above the current price in 90 days from now is about 17.14 (This Bioventus probability density function shows the probability of Bioventus Stock to fall within a particular range of prices over 90 days) .
Considering the 90-day investment horizon the stock has the beta coefficient of 1.04 suggesting Bioventus market returns are related to returns on the market. As the market goes up or down, Bioventus is expected to follow. Additionally Bioventus has an alpha of 0.1388, implying that it can generate a 0.14 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Bioventus Price Density |
| Price |
Predictive Modules for Bioventus
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Bioventus. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bioventus' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Bioventus Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Bioventus is not an exception. The market had few large corrections towards the Bioventus' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Bioventus, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Bioventus within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.14 | |
β | Beta against Dow Jones | 1.04 | |
σ | Overall volatility | 0.39 | |
Ir | Information ratio | 0.04 |
Bioventus Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bioventus for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bioventus can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Bioventus had very high historical volatility over the last 90 days | |
| Bioventus has high likelihood to experience some financial distress in the next 2 years | |
| Bioventus has 335.63 M in debt with debt to equity (D/E) ratio of 1.17, which is OK given its current industry classification. Bioventus has a current ratio of 0.92, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. That said, strategic use of leverage may enable Bioventus to fund expansion initiatives and generate superior returns. | |
| The entity reported the last year's revenue of 573.28 M. Reported Net Loss for the year was (318 K) with profit before taxes, overhead, and interest of 382.03 M. | |
| About 74.0% of Bioventus shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Stalnecker Susan M of 26493 shares of Bioventus subject to Rule 16b-3 |
Bioventus Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Bioventus Stock often depends not only on the future outlook of the current and potential Bioventus' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Bioventus' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 65.4 M | |
| Cash And Short Term Investments | 41.6 M |
Bioventus Fundamentals Growth
Bioventus Stock prices reflect investors' perceptions of the future prospects and financial health of Bioventus, and Bioventus fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bioventus Stock performance.
| Return On Equity | 0.0638 | ||||
| Return On Asset | 0.0414 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 799.49 M | ||||
| Shares Outstanding | 66.98 M | ||||
| Price To Earning | 6.96 X | ||||
| Price To Book | 3.13 X | ||||
| Price To Sales | 0.92 X | ||||
| Revenue | 573.28 M | ||||
| Gross Profit | 382.03 M | ||||
| EBITDA | 39.22 M | ||||
| Net Income | (318 K) | ||||
| Cash And Equivalents | 34.36 M | ||||
| Cash Per Share | 0.56 X | ||||
| Total Debt | 335.63 M | ||||
| Debt To Equity | 1.17 % | ||||
| Current Ratio | 0.94 X | ||||
| Book Value Per Share | 2.48 X | ||||
| Cash Flow From Operations | 38.8 M | ||||
| Earnings Per Share | 0.16 X | ||||
| Market Capitalization | 519.74 M | ||||
| Total Asset | 727.96 M | ||||
| Retained Earnings | (355.08 M) | ||||
| Working Capital | 65.21 M | ||||
About Bioventus Performance
Assessing Bioventus' fundamental ratios provides investors with valuable insights into Bioventus' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Bioventus is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 164.16 | 121.15 | |
| Return On Tangible Assets | (0.12) | (0.13) | |
| Return On Capital Employed | (0.03) | (0.03) | |
| Return On Assets | (0.05) | (0.06) | |
| Return On Equity | (0.26) | (0.27) |
Things to note about Bioventus performance evaluation
Checking the ongoing alerts about Bioventus for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bioventus help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bioventus had very high historical volatility over the last 90 days | |
| Bioventus has high likelihood to experience some financial distress in the next 2 years | |
| Bioventus has 335.63 M in debt with debt to equity (D/E) ratio of 1.17, which is OK given its current industry classification. Bioventus has a current ratio of 0.92, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. That said, strategic use of leverage may enable Bioventus to fund expansion initiatives and generate superior returns. | |
| The entity reported the last year's revenue of 573.28 M. Reported Net Loss for the year was (318 K) with profit before taxes, overhead, and interest of 382.03 M. | |
| About 74.0% of Bioventus shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Stalnecker Susan M of 26493 shares of Bioventus subject to Rule 16b-3 |
- Analyzing Bioventus' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bioventus' stock is overvalued or undervalued compared to its peers.
- Examining Bioventus' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bioventus' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bioventus' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bioventus' stock. These opinions can provide insight into Bioventus' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Bioventus Stock Analysis
When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.